Multi-relax 10 mg 20 tablets

Tradename:

Multi-relax

Composition:

Each tablet contains:

Cyclobenzaprine hydrochloride 10 mg

Properties:

Cyclobenzaprine relieves local skeletal muscle spasm without directly interfering with muscle function. Cyclobenzaprine has been shown to be ineffective in muscle spasms associated with central nervous system damage. In animal simulations, cyclobenzaprine reduced or abolished skeletal muscle hyperactivity. Research has shown that cyclobenzaprine does not affect neuromuscular synapses or skeletal muscle directly. These studies show that cyclobenzaprine acts primarily at the level of the brainstem, with only a secondary effect at the level of the spinal cord, although the effect on the latter may contribute to the overall relaxing effect of the drug on skeletal muscle. The effect of cyclobenzaprine is to reduce tonic somatic motor activity, affecting both gamma- (y-), and alpha- (a-) motor systems. Pharmacological studies have demonstrated the similarity of the effects of cyclobenzaprine and structurally related tricyclic antidepressants, including an antagonistic effect towards reserpine, potentiation of the action of norepinephrine, strong peripheral and central anticholinergic effects, and sedation.

Indications:

Multi-Relax is indicated for the elimination of muscle spasm, accompanied by acute pain from the musculoskeletal system, as an addition to a regimen of limited physical activity and physiotherapy exercises. The improvement is manifested by the elimination of muscle spasms and associated signs and symptoms, namely pain, increased sensitivity and restriction movement.

Method of administration and dosage:

Usually taken 5-10 mg 3 times a day. The maximum daily dose is 60 mg per day.

Contraindications:

hypersensitivity to any component of this drug. May manifest as an anaphylactic reaction, hives, swelling of the face and / or tongue, or itching. If you suspect a hypersensitivity reaction, stop taking the drug Multi-Relax@;

• joint use of monoamine oxidase inhibitors (MAO) or use within 14 days after stopping them;
• acute phase of myocardial infarction, arrhythmias, blockade of the cardiac conduction system, conduction disturbances or congestive heart failure.

Precautions:

With the development of clinically significant symptoms on the central nervous system, discontinuation of treatment with MultiRelax@ should be considered.
Cyclobenzaprine is structurally related to tricyclic antidepressants such as amitriptyline and imipramine. There have been reports that tricyclic antidepressants cause arrhythmias, sinus tachycardia, and increased pulse conduction time, leading to myocardial infarction and stroke. MultiRelax@ may enhance the effects of alcohol, barbiturates and other central nervous system depressants.

Side effects:

The most common adverse reactions (2 3%):

• sleepiness
• dizziness
• tiredness
• nausea

constipation

dyspepsia

Adverse reactions with a frequency of 1-3%:

fatigue

• sleepiness
• asthenia
• unpleasant taste

blurred vision

headache

• nervousness
• confusion of consciousness

Storage method:

At a temperature not higher than 30 degrees.

Packaging:

The cardboard box holds 20 tablets.